Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | AGXT | P21549 | 2/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.42 |
| ▸ | CDK9 | P50750 | 3/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4542812 | 1.00 | IDO1 (0.43) | IDO1AGXTCCNT1CDK9TAAR1 | |
| SCHEMBL3390402 | 0.88 | CCNT1 (0.46) | CCNT1CDK9HDAC1NPY5R | |
| SCHEMBL8959040 | 0.85 | IDO1 (0.42) | IDO1AGXTTAAR1MAOBLMNA | |
| SCHEMBL8959031 | 0.83 | IDO1 (0.46) | IDO1AGXTTAAR1MAOB | |
| SCHEMBL5301923 | 0.83 | POLB (0.45) | CCNT1CDK9HDAC1NPY5R | |
| SCHEMBL578004 | 0.82 | TSHR (0.41) | IDO1CCNT1CDK9NPY5R | |
| SCHEMBL1831290 | 0.81 | IDO1 (0.44) | IDO1CCNT1CDK9TAAR1HDAC1 | |
| SCHEMBL29427115 | 0.81 | IDO1 (0.44) | IDO1CCNT1CDK9TAAR1HDAC1 | |
| SCHEMBL1011680 | 0.81 | FDFT1 (0.46) | CCNT1CDK9 | |
| SCHEMBL28761877 | 0.80 | TAAR1 (0.43) | IDO1AGXTTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| US-20240246908-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2024-07-25 | — | — | US | disclosed |
| EP-4323338-A1 | TEAD INHIBITORS | Orion Corporation (FI) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022219246-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246908-A1 | TEAD INHIBITORS | TEAD3, TEAD1, TEAD2 | IDO1 2115/4885AGXT 2683/4885CCNT1 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.